In spite of this record, an FDA advisory panel voted 5-4 against approving the drug for breast cancer. While studies have shown that Avastin shrinks breast tumors, there is no evidence that it lengthens or improves the quality of patients' lives.
FDA Approves Breast Cancer Drug Avastin Despite Opposition by Advisory Panel
The Supreme Court on June 30 declined to to hear a censorship complaint brought by Health...
